Novo Nordisk Insulin - Search News

Novo Nordisk shares drop

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Reuters on MSN · 4d

Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks. The data is seen as crucial for the future potential for its experimental next-generation obesity drug,

Fox Business on MSN · 4d

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Fierce Pharma4d

Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Novo Nordisk foundation’s obesity head works as paid adviser to chocolate maker Ferrero

Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

10d

Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Medical Dialogues9h

CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results